

Taxol

=Abstract=

Taxol as Salvage Therapy in Patients with Recurrent Ovarian Carcinoma After First Line Chemotherapy

Do Hyung Kim, M.D., Sun Hwa Noh, M.D.,
Dong Hwi Kim, M.D., Un Dong Park, M.D.

Department of Obstetrics and Gynecology, College of Medicine Kosin Medical College, Pusan, Korea

As salvage therapy for recurrent ovarian cancer, Taxol has been tried alone or combined with cisplatin, or carboplatin.

Paclitaxel (Taxol) is an antineoplastic agent; isolated from the bark of the western yew which acts as an antimicrotubule agent.

In our study, 28 patients were eligible and assessable, Taxol was administered at a dose of 175 mg/m², infused over 3hr every 21 days.

A total of 161 courses of Taxol were infused, and the median treatment cycle was 6.25 cycles (1 to 16 cycles).

The overall response rate was 21.4%, but we found higher response rate in sensitive group to platinum combined therapy than resistant.

The median survival duration was 10.2 months and the median duration of follow up was 25.0 months.

The worst severe toxicity was grade 4 leukopenia and expiriment with sepsis.

39% of patients experienced myalgia and 25% experienced nausea, vomiting and diarrhea.

Other adverse effects were not important or considerable.

Taxol has been shown to be the most useful agent in patients with advanced ovarian cancer who had shown sensitivity with platinum previously, and Taxol has yielded low response rate in platinum-resistant patients.

Further more study is required about Taxol itself, its optimal dose, combining use with other antitumor agent, and as first line therapy in the treatment of advanced ovarian carcinoma.

Keywords: Paclitaxel, Ovarian cancer, Salvage therapy

가

- Taxol -

5 25% 30% stable disease) 가 25%
.1) 가 가
platinum (PD: progressive disease)
, platinum
(sensitive group) (resistant
가 가 Taxol2 group) Taxol
Taxol micro- platinum
tubule G2M phase 6
.3)
1996 Mayerhofer platinum 6
Taxol 25%
15 ,4) 1997 (progression free interval) Taxol
Ezcurdia platinum 1
Taxol 51.3%
10 16.8 28 Taxol 175 mg/m2
.3) , platinum 3 3
15%
platinum 6
Taxol (PR: partial response), (SD: stable disease)
16
(full dose)
Taxol Solumedrol 125 mg 12
4 , Diphenhydra-
mine(Avil[®]) 45.5 mg Cimetidine 300 mg 30
, platinum Taxol 20 3
1 3 GOG (Gynecologic
Oncology Group)
가 3,000 , GM-CSF
(colony stimulating factor) 200 µg 2
Taxol (CBC: complete
blood count), (UA), (RFT),
(LFT)
CA-125
가 4 2 CT
가
(CR: complete response),
50%
(PR: partial response),
가 4
가 (SD: 1.

28
age 51.5
15.9
가
(46.4%)

16
71
25
가 17 (60.7%)
13

(Table 1).

Table. 1.

Patients	No	28
Age	16 71(median age: 51.5 years)	
Stage		5(17.9%) 2(7.1%) 17(60.7%) 4(14.35)
Pathology	SCAC SPAC MCAC Endometrioid Ca Others(7.1%) Malignant Brenner tumor Undifferentiated Ca	13(46.45) 7(25.0%) 3(10.7%) 3(10.7%) 2(7.1%) 1 1
GOG performance status	Grade Grade	8 20
Platinum	sensitive group resistant group	21 7

SCAC: Serous Cyst Adenocarcinoma; SPAC: Serous Papillary Adenocarcinoma; MCAC: Mucinous Cyst Adenocarcinoma; Ca: Carcinoma; GOG: Gynecologic Oncology Group

Taxol 6.25 (1 16) 161

Taxol cytoxan/Carboplatin
18 가 , 7.0
(Table 2).

2. Taxol

Table 2. Prior Chemotherapy Regimen

Cytosan/Carboplatin	18 (mean: 7.0 cycles)
Cytosan/Carboplatin/Adriamycin	4 (mean: 8.3 cycles)
Cytosan/Platocin/Adriamycin	6 (mean: 5.7 cycles)

platinum 21 11.9
Taxol
2 3 23.8%
platinum 7 1 ,
4 , 2 14.3%
(Table 3), Taxol
21.4% , Taxol
10.2 .
3.
가 가 , 1
Taxol Grade 4 (leu-
kopenia)
Grade 2가 25%(7/28) 가
Grade 2가 7.6%(2/28) .
Grade 2가 7.6%(2/28)
가 . Grade 1 2
Grade 1 2 .
Grade 1 28.5%(8/28), Grade 2가 10.7
%(3/28) , .

(Table 4).

Mayerhofer 25% (11% ,
14%) ,4 McGuire 30%

Table 3. Response to Taxol in the overall patient population

Response	Platinum Sensitive Group N=21(%)	Platinum Resistant Group N=7(%)	All patients(%)
CR	2(9.5)	0(0)	2(7.2)
PR	3(14.3)	1(14.3)	4(14.3)
SD	5(23.8)	4(57.1)	9(32.1)
PD	11(52.4)	2(28.6)	13(46.4)

CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease

Table 4. Adverse effect after Taxol therapy

Adverse effect (WHO criteria)	Grade			
	1	2	3	4
Neutropenia	2	4	0	1
Thrombocytopenia	0	2	0	0
Anemia	1	7	1	0
Nausea/Vomiting	3	2	0	0
Diarrhea	2	0	0	0
Myalgia	8	3	0	0
Allergy	2	0	0	0
Hepatotoxicity	2	0	0	0

5) 21%

Taxol 175 mg/m² 3 3
 , McGuire 200 mg/m²
 250 mg/m² 24 3
 170 mg 24 3

가
 Taxol cisplatin .68
 boplatin Taxol car-
 가 ,

platinum
 Taxol
 23.8%, 14.3%
 Thigpen2
 가 platinum
 Taxol
 Myerhofer platinum
 Taxol

Taxol , Taxol
 가
 Taxol , Grade 4 leukopenia 1
 Grade 2 leukopenia GM-CSF

(Zofran[®])
 39%(11/28)

(GOT/GPT)

가
 가
 Taxol
 ,9) ,10)
 가 11-13)

, Taxol patinum

가 Topotecan,14) Etoposide15)

platinum
 28
 Taxol

1. 28 platinum 21
 2 (14.3%) 23.8% (9.5%) 3
 7 1 (14.3%)
 Taxol 21.4%
 2. platinum 11.9
 , platinum 5.6
 , Taxol 10.2
 15.9

3. Grade 4 leukopenia
 1 , grade 2
 25%(7/28), 39%(11/28), 25
 % (7/28), 7%(2/28)

Taxol platinum

1

3 23.6%
 Taxol platinum
 가 ,
 Taxol ,
 가 .

- References -

1. Pettersson F: Annual report on the results of treatment in gynecologic cancer. FIGO Vol 21. Int J Gynecol Obstet 1991;36:1-315.
2. Thigpen JT, Blessing JA, Ball H et al: Phase trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994;12(9): 1748-1753.
3. Ezcurdia L, Jovtis SL, Mickiewicz E et al: Paclitaxel in platinum-resistant ovarian cancer patient. Semin Oncol 1997;24(5):53-56(Suppl 15).
4. Mayerhofer K, Kucera E, Zeisler H et al: Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol 1997;64:109-113.
5. McGuire WP, Rowinsky EK, Rosenshein NB et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Intern Med 1989; 111:273-279.
6. McGuire WP, Hoskins WJ, Brady MF et al: Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage and stage ovarian cancer: a Gynecologic Oncology Group Study. Semin Oncol 1997; 24(1):13-16(Suppl 2).

7. Neijt JP, Engelholm SA, Witteveen PO et al: Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an Interim Analysis. Semin Oncol 1997;24(5):36-39(Suppl 15).
8. Lorraine EP, Guastalla JP, Weber B et al: Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a Multicenter French groupe investigateurs nationaux pour l'Etude des cancers ovariens phase study. Semin Oncol 1997;24(5):30-35(Suppl 15).
9. Bolis G, Scarfone G, Villa A et al: A phase trial with fixed-dose carboplatin and escalating dose of paclitaxel in advanced ovarian cancer. Semin Oncol 1997; 24(1):23-25(Suppl 2).
10. Miglietta L, Amoros D, Bruzzone M: Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase study. Oncology 1997;54:102-107.
11. Meerpohl HG, Bois A, Luck HJ et al: Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase trial. Semin Oncol 1997;24(1):17-22(Suppl 2).
12. S Karlos DV, Aravantinos G, Kosmidis P et al: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a hellenic cooperative oncology group study. Semin Oncol 1997;24(5):57-61(Suppl 15).
13. Bois A, Luck HJ, Meier W et al: Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. Semin Oncol 1997;24(4): 28-33(Suppl 11).
14. Dancy J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74:327-338.
15. Seymour MT, Mansi JL, Gallagher CJ et al: Protracted oral etoposide in epithelial ovarian cancer: a phase study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-195.